Anyone who’s fought a lifelong battle of the bulge – cutting calories, working out – might wonder why they still can’t lose ...
Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk ...
Holley Performance Brands (NYSE: HLLY), a leader in automotive aftermarket performance solutions, today announced financial ...
Commercial launch is on-track for ZUSDURI, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales ...
I revved up my longevity protocols and sought out the latest predictive screenings. Was I seizing control of my health or ...
Urogen Pharma (NASDAQ:URGN) executives used the company’s fiscal 2025 earnings call to highlight early commercial momentum ...
Seed packets look simple, but they often hide key instructions and use confusing jargon. Especially for new gardeners who ...
First industry benchmark report exposes critical gap between adoption and governance in customer training programs.
A growing body of research suggests engagement in the arts supports psychological well-being, helping young people manage ...
Chief Commercial Officer David Lin reported, “ZUSDURI generated $1.8 million in net product revenue in Q3, and $14 million in Q4, bringing full year 2025 revenue to $15.8 million,” and detailed ...
Q4 2025 Earnings Call March 3, 2026 4:30 PM ESTCompany ParticipantsPatrick Soon-Shiong - Founder, Executive Chairman and ...
Sociodemographic Disparities in Outcomes, Costs, and Care in Obstructive Hypertrophic Cardiomyopathy
Patients with oHCM experience significant variation in cardiovascular events, health care resource use, and costs across age, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results